Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Pluristem Therapeutics Inc., a leading biotechnology company, announced topline results from its multinational double-blind, placebo-controlled phase III study.

Pluristem Therapeutics Inc. and Tnuva Group jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat.

Leading biotechnology company Pluristem Therapeutics Inc. and Israel’s largest food producer Tnuva Group announced the closing of its landmark collaboration to develop, manufacture and commercialize cell-based products for the food industry.

Pluristem Therapeutics Inc., a leading biotechnology company, issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.

Pluristem Therapeutics Inc. today announced positive final results from its innovative hematology Phase I study to evaluate the safety and exploratory efficacy of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following HCT

Pluristem Therapeutics Inc., a leading biotechnology company, and Tnuva Group, Israel’s largest food producer, announced the launch of an innovative collaboration to develop, manufacture and commercialize cultured cell-based products for the food industry.

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products (“Pluristem” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of $6.30 per share in a registered direct offering, for gross proceeds of $30 million before deducting placement agent fees and expenses.

Pluristem Therapeutics Inc., a leading biotechnology company, announced that it has received approval for an additional grant from the Israel Innovation Authority to support research based on its cutting-edge PLX platform.

The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.